Stanley C. Erck is the President and CEO of Novavax, Inc., a biotechnology company known for developing vaccines against infectious diseases. He joined Novavax in 2011 and has been a significant figure in the company’s journey, especially in the context...

Stanley C. Erck is the President and CEO of Novavax, Inc., a biotechnology company known for developing vaccines against infectious diseases. He joined Novavax in 2011 and has been a significant figure in the company’s journey, especially in the context of the COVID-19 pandemic. Under his leadership, the company achieved both emergency use authorization and provisional approvals for its COVID-19 vaccine, NVX-CoV2373, on various global platforms. Prior to Novavax, he was the CEO of Iomai Corporation, a vaccine developer that was acquired in 2008. Erck's experience also includes holding leadership positions at Procept and Integrated Genetics, which is part of Sanofi Genzyme. A noteworthy fact is that during the peak of the pandemic in 2020, he executed several large insider trades, selling shares worth a total of over 12 million dollars, which indicates both confidence and substantial involvement in his company’s stock performance. While his compensation in 2023 saw a significant drop as he transitioned towards retirement, it included consulting fees and vested stocks that highlighted his long-term commitment to Novavax. Erck is also involved with multiple boards, including BioCryst Pharmaceuticals and MaxCyte, showcasing his broad influence in the biotech sector.